NumFin

Paratek Pharmaceuticals, Inc.

Symbol: PRTK

NASDAQ

2.23

USD

Market price today

  • -3.0521

    P/E Ratio

  • 0.1791

    PEG Ratio

  • 127.83M

    MRK Cap

  • 0.00%

    DIV Yield

Paratek Pharmaceuticals, Inc. (PRTK) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for Paratek Pharmaceuticals, Inc. (PRTK). Companys revenue shows the average of 22.574 M which is 22.363 % gowth. The average gross profit for the whole period is 19.805 M which is 22.423 %. The average gross profit ratio is 0.849 %. The net income growth for the company last year performance is 0.076 % which equals -0.435 % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of Paratek Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.062. In the realm of current assets, PRTK clocks in at 136.842 in the reporting currency. A significant portion of these assets, precisely 34.248, is held in cash and short-term investments. This segment shows a change of -0.641% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 258.414 in the reporting currency. This figure signifies a year_over_year change of 0.010%. Shareholder value, as depicted by the total shareholder equity, is valued at -171.042 in the reporting currency. The year over year change in this aspect is 0.338%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 78.038, with an inventory valuation of 16.57, and goodwill valued at 0.83, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 5.31 and 0, respectively. The total debt is 258.41, with a net debt of 224.17. Other current liabilities amount to 32.08, adding to the total liabilities of 343.58. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420022001

balance-sheet.row.cash-and-short-term-investments

178.9734.295.5125.2
215.4
292.8
151.7
128
131.3
95.9
70
85.3
62.4
68
88.9
85.1
94.6
64.6
50.5
46.6
0
0

balance-sheet.row.short-term-investments

29.92015.120
113.1
203.4
116.3
75.1
0
0
60.1
45.9
51.7
54.3
71.9
70.2
69.9
50.1
14.5
38.4
0
0

balance-sheet.row.net-receivables

190.457833.115.7
9.6
0.2
5.9
0.3
0.7
4.4
2.9
0.3
0
0
0
0.5
11.5
0.2
0.2
0.5
0
0

balance-sheet.row.inventory

62.7216.61114.6
11.6
-42.2
0.2
0.8
2.4
0
-2.9
8.3
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

41.917.912.47.8
6.5
4.4
2.7
2.9
7.9
1
3.6
1.1
3.5
1.5
1.5
0.5
1.6
0.9
0
0
0
0

balance-sheet.row.total-current-assets

474.42136.8152.1164.1
243.4
255.2
160.5
132.1
142.4
101.3
73.6
95
65.8
69.4
90.4
86
107.8
65.7
51.7
47.6
0
0

balance-sheet.row.property-plant-equipment-net

8.632.42.63
3.7
1.2
1.7
1.2
0.8
0
0
0.1
0.3
0.6
1.1
0
1.1
0.1
0.3
0.2
0
0

balance-sheet.row.goodwill

3.320.80.80.8
0.8
0.8
0.8
0.8
0.8
0.8
0
3
3
3
3
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0.1
1
1.3
4.8
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

3.320.80.80.8
0.8
0.8
1
1.8
2.2
5.6
0
3
3
3
3
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
42.5
0
0
0
0
0
0
0
0
0
0
40.4
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

140.1132.528.48.9
3.2
0.5
0.5
0.6
0.5
2.9
0
0
0
0.8
0.8
0.8
-39.4
0.2
0.3
0.2
0
0

balance-sheet.row.total-non-current-assets

152.0635.731.812.7
7.7
44.9
3.2
3.6
3.5
8.6
0
3.1
3.3
4.4
4.8
0.8
2
0.4
0.5
0.4
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

626.48172.5183.9176.9
251.1
300.2
163.7
135.7
145.9
110
73.7
98.1
69.2
73.8
95.2
86.8
109.8
66.1
52.3
48
41.9
3.9

balance-sheet.row.account-payables

21.685.35.41.8
4.1
2.1
3.6
4.4
0.8
0.5
0.4
1
1
0.6
0.7
1.1
4.2
2.4
2.6
1.4
0
0

balance-sheet.row.short-term-debt

164.04000
0
0
0
0
0
0
0
0
0
1.4
0.5
0
5
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

872.3258.4255.7252
262.8
229
59.2
39
19.6
0
0
0
0
0
0.6
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
7.4
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

91.232.125.922.1
20.1
15.6
13.2
16
19.7
3.3
1.5
1.7
2.4
0.4
2.4
1.6
0
3.8
2.1
1.3
0
0

balance-sheet.row.total-non-current-liabilities

1042.35306.2280.4255.2
266.5
234.9
64.4
43.7
24.2
11
0
0
0.1
0.3
8.1
0.1
44.9
0
108
82.9
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

4.891.51.31.5
2.1
0
0
0
0
0
0
0
0
0
0.9
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1354.08343.6311.7279.1
290.7
252.6
81.2
64.1
44.7
14.7
1.9
2.7
3.4
10
24.1
2.8
64.1
6.2
112.7
85.6
0
0

balance-sheet.row.preferred-stock

0000
0
0
0
135.7
145.9
110
0
0
0
0
95.2
0
25.1
66.1
0
0
0
0

balance-sheet.row.common-stock

0.230.10.1705.5
671.5
630.2
552.7
0
370
0
211.3
207.5
165.8
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3769.48-930.4-866.9-807.8
-711.3
-582.5
-470.1
-380.4
-268.7
-197.9
-139.6
-112.1
-100.1
-96.2
-86.9
-89.1
-123.9
-91.4
-61.7
-37.9
-7.2
-1.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.12000
0.1
-0.1
-0.2
0
-515.9
-110
0
0
0
0
0
0.4
-0.1
-1.3
-2.2
-0.1
0
0

balance-sheet.row.other-total-stockholders-equity

3041.77759.4739.10
-0.1
0.1
0.2
316.2
-145.9
183.1
0
0
0
160
62.7
172.7
144.6
86.4
3.5
0.5
0.2
0.1

balance-sheet.row.total-stockholders-equity

-727.6-171-127.8-102.3
-39.7
47.7
82.6
71.6
101.2
95.2
71.7
95.4
65.8
63.8
71.1
84
45.7
59.8
-60.4
-37.6
-7
-1.5

balance-sheet.row.total-liabilities-and-stockholders-equity

626.48172.5183.9176.8
251
300.3
163.9
135.7
145.9
110
73.7
98.1
69.2
73.8
95.2
86.8
109.8
66.1
52.3
48
41.9
3.9

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-727.6-171-127.8-102.3
-39.7
47.7
82.6
71.6
101.2
95.2
71.7
95.4
65.8
63.8
71.1
84
45.7
59.8
-60.4
-37.6
-7
-1.5

balance-sheet.row.total-liabilities-and-total-equity

626.48---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

29.92015.120
113.1
245.9
116.3
75.1
0
0
60.1
45.9
51.7
54.3
71.9
70.2
69.9
50.1
14.5
38.4
0
0

balance-sheet.row.total-debt

1036.34258.4255.7252
262.8
229
59.2
39
19.6
0
0
0
0
0
1.1
0
0
0
0
0
0
0

balance-sheet.row.net-debt

887.3224.2175.4146.9
160.5
-63.9
-92.5
-14
-111.7
-95.9
-9.9
-39.4
-10.7
-13.7
-15.9
-14.9
-24.7
-14.4
-36
-8.2
0
0

Cash Flow Statement

The financial landscape of Paratek Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.360. The company recently extended its share capital by issuing 7.33, marking a difference of 7.692 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 7.68 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 14804000.000 in the reporting currency. This is a shift of 2.282 from the previous year. In the same period, the company recorded 0.49, 0, and -2.89, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0.65, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

-62.73-63.6-59.1-96.5
-128.8
-112.4
-89.1
-111.6
-70.9
-17.8
-27.4
-12
0
-9.3
-21.8
34.8
-32.5
-29.6
-23.8
-18

cash-flows.row.depreciation-and-amortization

0.310.50.40.6
-1.3
-1.1
1.3
2.3
0.7
0.2
0.1
0.2
0.4
0.5
0.6
1.1
0.5
0.7
0.5
0.1

cash-flows.row.deferred-income-tax

0001.1
0
0.1
0.7
0
2.9
9.1
0
0
0
0
1.2
0.1
0
0
0
0

cash-flows.row.stock-based-compensation

10.3412.314.310.2
14.3
25.5
16.9
10.8
5.1
0.7
3.3
2.9
4.4
1.9
1.4
2.8
0
0
0
0

cash-flows.row.change-in-working-capital

23.96-20.8-8.2-20.3
-21.5
3.9
-8.2
4.5
10.5
-11.5
5.4
-6.7
-7.5
-13.6
19.7
-48.6
45.5
1.8
1.7
0.8

cash-flows.row.account-receivables

-5.71-40.4-21.8-7.5
-11.2
4.4
-4.8
5
-2.7
-4.8
0
0
0
0
0
11.5
0
0
0
0

cash-flows.row.inventory

-2.05-9.1-15.5-11.8
-10.9
-0.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

8.967.76.81.6
-0.6
-0.6
0
0
0
0
-0.6
0
0.4
-0.1
0.2
0
0
0
0
0

cash-flows.row.other-working-capital

22.762122.3-2.6
1.2
0.8
-3.4
-0.4
13.2
-6.7
6
-6.7
-7.9
-13.5
19.5
-60.1
45.5
1.8
1.7
0.8

cash-flows.row.other-non-cash-items

4.915.44.31.5
3.2
2.7
0.6
-0.1
-0.1
9.9
3.8
0.4
-2.9
1
1
-1.1
4.3
1.2
0.1
0

cash-flows.row.net-cash-provided-by-operating-activities

-23.22000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.070-0.4-0.4
-0.2
-0.1
-1.1
-0.7
-0.9
0
0
0
-0.1
-0.1
-0.3
0
-1.1
0
-0.2
-0.1

cash-flows.row.acquisitions-net

0000
-0.2
-0.7
0
0
0
13.7
0
0
0
0
48
0
0
0
0
0

cash-flows.row.purchases-of-investments

-15.16-15.2-15.1-29.6
-102.2
-292.9
-180.3
-135.8
0
0
-69.8
-41
-52.2
-106.6
-128.3
-135.6
-128.4
-97.2
-16.3
-51.1

cash-flows.row.sales-maturities-of-investments

303020122.5
237
165.1
138.7
60.1
0
0
54.7
46.3
53.5
122.8
95.3
136.6
108.8
61.5
40.4
52.3

cash-flows.row.other-investing-activites

15.2000
0.2
0.7
0.7
1.6
0.3
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

29.9714.84.592.5
134.6
-127.9
-42
-74.8
-0.6
13.7
-15.1
5.2
1.3
16.1
14.7
1
-20.6
-35.6
23.9
1

cash-flows.row.debt-repayment

-3.73-2.9-0.3-70
0
0
0
0
0
0
0
0
0
0
-3.4
0
0
0
0
0

cash-flows.row.common-stock-issued

07.318.421.9
26.6
51.5
82.8
70.9
71.3
89.8
0.4
38.7
1.4
0.2
0.5
0.1
13.2
39.9
25.4
0.1

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-0.120.70.359.4
31.1
169.2
20.2
19.6
19.5
9.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-3.575.118.311.3
57.6
220.7
103
90.5
90.7
99.5
0.4
38.7
1.4
0.2
-2.9
0.1
13.2
39.9
25.4
0.1

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

3.18-46.2-25.40.4
58.1
11.7
-17.5
-78.3
35.4
94.6
-29.4
28.7
-3.1
-3.3
12.6
-9.8
10.3
-21.6
27.8
-15.9

cash-flows.row.cash-at-end-of-period

149.5534.480.6106
105.6
47.5
35.4
53
131.3
95.9
9.9
39.4
10.7
13.7
17
14.9
24.7
14.4
36
8.2

cash-flows.row.cash-at-beginning-of-period

146.3780.6106105.6
47.5
35.8
53
131.3
95.9
1.2
39.4
10.7
13.7
17
4.4
24.7
14.4
36
8.2
24.1

cash-flows.row.operating-cash-flow

-23.22-66.1-48.3-103.4
-134
-81.2
-78.6
-94.1
-54.7
-18.5
-14.8
-15.2
-5.7
-19.5
0.8
-10.9
17.7
-25.9
-21.5
-17.1

cash-flows.row.capital-expenditure

-0.070-0.4-0.4
-0.2
-0.1
-1.1
-0.7
-0.9
0
0
0
-0.1
-0.1
-0.3
0
-1.1
0
-0.2
-0.1

cash-flows.row.free-cash-flow

-23.29-66.2-48.6-103.8
-134.3
-81.2
-79.7
-94.8
-55.5
-18.5
-14.8
-15.2
-5.8
-19.6
0.5
-10.9
16.6
-25.9
-21.6
-17.2

Income Statement Row

Paratek Pharmaceuticals, Inc.'s revenue saw a change of 0.247% compared with the previous period. The gross profit of PRTK is reported to be 127.73. The company's operating expenses are 173.94, showing a change of 23.761% from the last year. The expenses for depreciation and amortization are 0.49, which is a 1.942% change from the last accounting period. Operating expenses are reported to be 173.94, which shows a 23.761% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.123% year-over-year growth. The operating income is -46.21, which shows a 0.123% change when compared to the previous year. The change in the net income is 0.076%. The net income for the last year was -63.57.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001

income-statement-row.row.total-revenue

167.74150.812143.5
16.5
17.1
12.6
0
0
4.3
1.7
11
19.7
12.5
5.2
60.6
16.7
0.4
0.1
1.1
1.3
0.4
0

income-statement-row.row.cost-of-revenue

25.323.121.58.7
3.5
0
0
0
0
0
0
0
0
2
2.2
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

142.45127.799.434.9
13.1
17.1
12.6
0
0
4.3
1.7
11
19.7
10.5
3
60.6
16.7
0.4
0.1
1.1
1.3
0.4
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

38.83---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-7.38-9.5-9.2-3.4
0
0
0
0
0
-0.3
3
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

186.99173.9140.5110.4
128.7
121.2
97
109.9
70.8
10.9
26.2
22.9
23.5
21.7
25.1
28.6
53.3
33.1
24.9
19.9
0
6.2
1.6

income-statement-row.row.cost-and-expenses

212.29197162.1119
132.2
121.2
97
109.9
70.8
10.9
26.2
22.9
23.5
21.7
25.1
28.6
53.3
33.1
24.9
19.9
0
6.2
1.6

income-statement-row.row.interest-income

0.990.80.11.5
3.6
3.3
1.4
1.1
0
0
0
0
0.1
0.1
0.3
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

18.8618.117.420.2
16.4
11
5.1
3.2
0.8
0.7
-0.1
-0.2
0
0
0.2
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-12.98-17.3-17.4-21
-12.9
-0.1
-0.2
0.3
0.7
-10.6
-3
-0.2
-0.2
-0.2
-2.1
2.8
4.1
3.1
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-7.38-9.5-9.2-3.4
0
0
0
0
0
-0.3
3
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-12.98-17.3-17.4-21
-12.9
-0.1
-0.2
0.3
0.7
-10.6
-3
-0.2
-0.2
-0.2
-2.1
2.8
4.1
3.1
0
0
0
0
0

income-statement-row.row.interest-expense

18.8618.117.420.2
16.4
11
5.1
3.2
0.8
0.7
-0.1
-0.2
0
0
0.2
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.951.30.41.6
3.5
-1.1
1.3
2.3
0.7
0.2
0.1
0.2
0.4
0.5
0.6
1.1
0.5
0.7
0.5
0.1
0
0
0

income-statement-row.row.ebitda-caps

-43.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-44.54-46.2-41.1-75.5
-115.6
-104.1
-84.6
-109.5
-70.1
-7.8
-27.4
-11.9
-3.8
-9.2
-22.1
32
-36.7
-32.7
-24.9
-18.8
1.3
-5.9
-1.6

income-statement-row.row.income-before-tax

-62.56-63.5-58.5-96.5
-128.5
-111.9
-88.3
-111.6
-70.9
-17.8
-27.4
-12
-4
-9.4
-24.1
34.8
-32.5
-29.6
0
0
0
0
0

income-statement-row.row.income-tax-expense

4.560.10.619.7
0.3
0.5
0.8
3.2
0
0.4
2.9
-0.2
-0.4
0.1
1.4
-2.8
-4.1
-3.1
-1.1
-0.8
12.8
5.6
1.6

income-statement-row.row.net-income

-67.12-63.6-59.1-116.3
-128.8
-112.4
-89.1
-111.6
-70.9
-17.8
-27.4
-12
-3.9
-9.3
-21.8
34.8
-32.5
-29.6
-23.8
-18
-12.8
-5.6
-1.6
Similar Stocks
You may also be interested in:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Frequently Asked Question

What is Paratek Pharmaceuticals, Inc. (PRTK) total assets?

Paratek Pharmaceuticals, Inc. (PRTK) total assets is 172538000.000.

What is enterprise annual revenue?

The annual revenue is 67270000.000.

What is firm profit margin?

Firm profit margin is 0.850.

What is company free cash flow?

The free cash flow is -0.190.

What is enterprise net profit margin?

The net profit margin is -0.299.

What is firm total revenue?

The total revenue is -0.201.

What is Paratek Pharmaceuticals, Inc. (PRTK) net profit (net income)?

The net profit (net income) is -63566000.000.

What is firm total debt?

The total debt is 258414000.000.

What is operating expences number?

The operating expences are 173941000.000.

What is company cash figure?

Enretprise cash is 42685000.000.